Nebenwirkungen · Simponi
Simponi 45 mg/0.45 mL solution for injection in pre-filled pen · Abschnitt 4.8 · PDF-Seite 10
HOS-121039 · Präparat HOS-095257
Tabulated list of adverse reactions ARs observed in clinical studies and reported from world-wide post-marketing use of golimumab are listed in Table 2. Within the designated system organ classes, the ARs are listed under headings of frequency and using the following convention: very common (≥ 1/10); common (≥ 1/100 to < 1/10); uncommon (≥ 1/1,000 to < 1/100); rare (≥ 1/10,000 to < 1/1,000); very rare (< 1/10,000); not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-01-30T15:08:00Z · SHA-256 9c07aa0af39af47a872fdf98b4749f232dd8d93a2e23d0c5c99feea1d99b8bfd · Passage 52b24515df094acfeee809a491869d1ce8bc2ad768b8d200d3f941ad06d10f55 · Zeichen 687–1262 im Abschnitt